<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04412564</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-B3101-II-03</org_study_id>
    <nct_id>NCT04412564</nct_id>
  </id_info>
  <brief_title>A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor</brief_title>
  <official_title>A Open-label, Single-arm Phase Ⅱ Clinical Trial of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate efficacy and safety of TQ-B3101 in subjects with
      advanced malignant tumor.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>The occurrence of all adverse events (AE) and serious adverse events (SAE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>PFS defined as the time from first dose until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Advanced Malignant Tumor</condition>
  <arm_group>
    <arm_group_label>TQ-B3101 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-B3101 capsules 300mg bid administered orally in 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B3101</intervention_name>
    <description>TQ-B3101 is a ALK inhibitor.</description>
    <arm_group_label>TQ-B3101 capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1; Life
        expectancy ≥12 weeks.

        2. Understood and signed an informed consent form. 3. Histologically or cytologically
        confirmed advanced malignant solid tumors. 4. Adequate organ system function. 5. Patients
        need to adopt effective methods of contraception.

        Exclusion Criteria:

          -  1. Has multiple factors affecting oral medication. 2. The toxicity of previous
             antitumor treatment is not recovered to ≤ grade 1. 3. Other malignancies occurred
             within 3 years, with exception of cured cervical carcinoma in situ, non-melanoma skin
             cancer and superficial bladder tumors.

             4. Has a history of hypertension, hypertensive encephalopathy or uncontrolled
             hypertension.

             5. Has cardiovascular and cerebrovascular diseases. 6. Has received radiotherapy,
             chemotherapy, surgery less than 4 weeks before the first dose.

             7. Has central nervous system metastasis and / or spinal cord compression, cancerous
             meningitis, and meningeal disease.

             8. Active hepatitis, HIV positive, syphilis positive. 9. Has a history of psychotropic
             substance abuse. 10. According to the judgement of the researchers, there are other
             factors that subjects are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongming Pan, Doctor</last_name>
    <email>Shonco@sina.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Chest Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xuhong Min</last_name>
      <email>1320722827@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xuhong Min</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Anhui medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230601</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhendong Chen</last_name>
      <email>chenzhendong@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Zhendong Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Wang, Doctor</last_name>
      <email>wangyanyifu@126.com</email>
    </contact>
    <investigator>
      <last_name>Yan Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fifth Medical Center of PLA Ceneral Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongjun Gao</last_name>
      <email>gaohj6709@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Hongjun Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102218</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhuo Yu, Doctor</last_name>
      <email>yuzhuo@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Zhuo Yu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wu Zhuang</last_name>
      <email>zhuangwu2008@126.com</email>
    </contact>
    <investigator>
      <last_name>Wu Zhuang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>501195</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weidong Li</last_name>
      <email>lwdlyn_hky@126.com</email>
    </contact>
    <investigator>
      <last_name>Weidong Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianhang He, Doctor</last_name>
      <phone>020-83062807</phone>
      <email>hejx@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Jianhang He, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liuzhou People's Hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi Zhuang Autonomous Region</state>
        <zip>545006</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Rixin Chen</last_name>
      <email>crxcyh@163.com</email>
    </contact>
    <investigator>
      <last_name>Rixin Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Yu, Doctor</last_name>
      <email>gpyuyan@163.com</email>
    </contact>
    <investigator>
      <last_name>Yan Yu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AnYang Tumor Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <zip>455000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junsheng Wang</last_name>
      <email>1207741934@qq.com</email>
    </contact>
    <investigator>
      <last_name>Junsheng Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luoyang Central Hospital Affiliated to Zhenghzou University</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471009</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhidong Pei</last_name>
      <email>peizhidong2728@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhidong Pei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanyang First People's Hospital</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>473000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xulin Zhao</last_name>
      <email>zlkzxl@163.com</email>
    </contact>
    <investigator>
      <last_name>Xulin Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shundong Cang, Doctor</last_name>
      <email>cangshundong@163.com</email>
    </contact>
    <investigator>
      <last_name>Shundong Cang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhiyong Ma</last_name>
    </contact>
    <investigator>
      <last_name>Zhiyong Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanping Hu</last_name>
      <email>h-y-p@126.com</email>
    </contact>
    <investigator>
      <last_name>Yanping Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangyang First People's Hospital</name>
      <address>
        <city>Xiangyang</city>
        <state>Hubei</state>
        <zip>441099</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xinxuan Wen</last_name>
      <email>1779477582@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xinxuan Wen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lin Wu, Doctor</last_name>
      <email>wulin-calf@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Lin Wu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yongqian Shu, Doctor</last_name>
      <email>shuyongqian@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Yongqian Shu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Gu, Doctor</last_name>
      <email>cxw0028@126.con</email>
    </contact>
    <investigator>
      <last_name>Wei Gu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116027</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yang Zhang, Doctor</last_name>
      <email>1592855479@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yang Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weihai Central Hospital</name>
      <address>
        <city>Weihai</city>
        <state>Shandong</state>
        <zip>264400</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Houqiang Li</last_name>
      <email>wendengliuhouqiang@163.com</email>
    </contact>
    <investigator>
      <last_name>Houqiang Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiaotong University Affiliated Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shun Lu, Doctor</last_name>
      <email>Shun_lu@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Shun Lu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qi Li, Doctor</last_name>
      <email>leeqi2001@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Qi Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Bethuen Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Mengxian Zhang, Doctor</last_name>
      <email>zhangmx73@163.com</email>
    </contact>
    <investigator>
      <last_name>Mengxian Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of PLA Air Force Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Haizhou Su, Doctor</last_name>
      <email>suhc@fummu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Haizhou Su, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yu Yao, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Yu Yao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xi'an Chest Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710100</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Juanwen Lian</last_name>
      <email>L85325060@163.com</email>
    </contact>
    <investigator>
      <last_name>Juanwen Lian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Diansheng Zhong</last_name>
      <email>zhongdsh@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Diansheng Zhong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Kai Li, Doctor</last_name>
      <email>likai_fnk@163.com</email>
    </contact>
    <investigator>
      <last_name>Kai Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Kashgar Prefecture</name>
      <address>
        <city>Kashgar Prefecture</city>
        <state>Xinjiang Uygur Autonomous Region</state>
        <zip>844000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuhua Wu</last_name>
      <email>68161592@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yuhua Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital, School of Medicine, Shihezi University</name>
      <address>
        <city>Shihezi</city>
        <state>Xinjiang Uygur Autonomous Region</state>
        <zip>832000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ping Gong, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Ping Gong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang Uygur Autonomous Region</state>
        <zip>830011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Rui Mao, Doctor</last_name>
      <email>42492768@qq.com</email>
    </contact>
    <investigator>
      <last_name>Rui Mao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Cancer Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang Uygur Autonomous Region</state>
        <zip>830011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chunling Liu</last_name>
      <email>liudeyouxiang66@163.com</email>
    </contact>
    <investigator>
      <last_name>Chunling Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongming Pan, Doctor</last_name>
      <email>Shonco@sina.cn</email>
    </contact>
    <investigator>
      <last_name>Hongming Pan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yiping Zhang</last_name>
      <email>zyp352@163.com</email>
    </contact>
    <investigator>
      <last_name>Yiping Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

